

*AMENDMENTS TO THE SPECIFICATION*

After the title, please insert the following:

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED  
ELECTRONICALLY

Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 5,000 Byte ASCII (Text) file named "234872sequence.2.TXT," created on August 20, 2007.

Please replace paragraph [0011] which begins on page 3, with the following:

[0011] Desirably, the patient, from whom the T-lymphocytes are obtained, has been immunized with an antigen of the cancer in accordance with methods known in the art (see, e.g., Rosenberg et al., Nat. Med. 4: 321-327 (1998)). If TILs are obtained from the patient, the prior immunization of the patient with an antigen of the cancer is optional. Preferably, the antigen of the cancer is one that induces a strong immune response against the cancer in the patient. For example, if the cancer is melanoma, preferably the patient is immunized with gp100, more preferably amino acids 209-217 of gp100, and most preferably amino acids 209-217 of gp100 with a methionine substitution at position 210, referred to herein as 209-2M peptide, which peptide has the amino acid sequence IMDQVPFSV (SEQ ID NO: 5). Her-2/Neu is a preferred antigen for immunization of a patient to be treated for breast cancer. If the patient has prostate cancer, preferably the patient is immunized with prostate-specific antigen (PSA). A patient with colon cancer is preferably immunized with carcinoembryonic antigen (CEA). These antigens are exemplary and are not intended to be limiting.